Why the Reiteration?
Pinnacle West posted inspiring earnings results in the first quarter of 2013, widely surpassing our expectation. The company outperformed on the back of positive non-fuel rate changes and favorable retail sales.
Nevertheless, our reiteration takes into consideration the impact of the Obama climate plan which calls for reduction in coal-fired operations in the future. This will inevitably take a toll on Pinnacle West�� coal-generation business, which forms a major part of its operational mix.
Also, the lingering weak economic fundamentals in the U.S. will continue to prevent electric prices from gaining momentum thereby deterring Pinnacle West�� opportunities.
Yet, the company�� gradual shift to renewable energy sources will bode well for its future broad growth objectives. Pinnacle West has a series of solar investments in the pipeline in Arizona which will elevate its clean energy generation share to 15% by 2025. This will be further supported by consistent customer additions expected in the next 3 years.
Hot Railroad Stocks To Invest In 2015: Merrimack Pharmaceuticals Inc (MACK)
Merrimack Pharmaceuticals, Inc., incorporated in 1993, is a biopharmaceutical company discovering, developing and preparing to commercialize medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. The Company�� product candidates include MM-398, MM-121, MM-111, MM-302 and MM-151. As of June 31, 2011, the Company owned approximately 74% interest of Silver Creek.
The Company�� Network biology is an interdisciplinary approach to drug discovery and development that enables the Company to build functional and predictive computational models of biological systems based on quantitative, kinetic, multiplexed biological data. The Company provides its scientists with insights into how the complex molecular interactions that occur within cell signaling pathways, or networks, regulate cell decisions and how dysfunction within these networks leads to disease. The Company applies network biology throughout the research and development process, including for target identification, lead compound design and optimization, diagnostic discovery, in vitro and in vivo predictive development and the design of clinical trial protocols.
MM-398
MM-398 is a stable nanotherapeutic encapsulation, or enclosed sphere carrying an active drug, of the marketed chemotherapy drug irinotecan. MM-398 achieved its primary efficacy endpoints in Phase 2 clinical trials in pancreatic and gastric cancer. In an open label, single arm Phase 2 clinical trial of MM-398 as a monotherapy in 40 metastatic pancreatic cancer patients who had previously failed treatment with gemcitabine, patients treated with MM-398 achieved median overall survival of 22.4 weeks. Additionally, 20% of the patients in this Phase 2 trial survived for more than one year, and the Company observed a disease control rate, meaning patients exhibited stable disease or partial or complete response to treatment, of 47.5% at six weeks.
The Company focuses on initiati! ng a Phase 3 clinical trial of MM-398 for the treatment of patients with metastatic pancreatic cancer who have previously failed treatment with gemcitabine. The trial is expected to enroll approximately 250 patients and is designed to compare the efficacy of MM-398 as a monotherapy against the combination of the chemotherapy drugs fluorouracil, or 5-FU, and leucovorin. There are multiple ongoing Phase 1 and Phase 2 clinical trials of MM-398. In July 2011, the United States Food and Drug Administration (FDA) granted MM-398 orphan drug designation for the treatment of pancreatic cancer.
MM-121
MM-121 is a fully human monoclonal antibody that targets ErbB3, a cell surface receptor, or protein attached to the cell membrane that mediates communication inside and outside the cell, that the Company�� network biology approach identified as a target in a range of cancers. A monoclonal antibody is a type of protein normally produced by cells of the immune system that binds to just one epitope, or chemical structure, on a protein or other structure. MM-121 is designed to inhibit cancer growth directly, restore sensitivity to drugs to which a tumor has become resistant and delay the development of resistance of a tumor to other agents. In collaboration with Sanofi, the Company focuses on testing MM-121 in combination with both chemotherapies and other targeted agents across a range of spectrum of solid tumors, including lung, breast and ovarian cancers. The Company partnered MM-121 with Sanofi after it initiated Phase 1 clinical development of the product candidate.
MM-111
MM-111 is a bispecific antibody designed to target cancer cells that are characterized by overexpression of the ErbB2 cell surface receptor, also referred to as HER2. A bispecific antibody is a type of antibody that is able to bind simultaneously to two distinct proteins or epitopes. The Company�� network biology approach identified that ligand-induced signaling through the complex of ErbB2 ! (HER2) an! d ErbB3 is a promoter of tumor growth and survival than previously appreciated.
MM-302
MM-302 is a nanotherapeutic encapsulation of doxorubicin with attached antibodies that are designed to target MM-302 to cells that over express the ErbB2 (HER2) receptor. The Company is conducting a Phase 1 clinical trial of MM-302 in patients with advanced ErbB2 (HER2) positive breast cancer.
MM-151
MM-151 is an oligoclonal therapeutic consisting of a mixture of three fully human monoclonal antibodies designed to bind to non-overlapping epitopes of the epidermal growth factor receptor (EGFR). EGFR is also known as ErbB1. An oligoclonal therapeutic is a mixture of two or more distinct monoclonal antibodies. The Company has designed MM-151 to block signal amplification that occurs within the ErbB cell signaling network. The Company has submitted an investigational new drug application (IND), to the FDA for MM-151 in July 2011.
Advisors' Opinion:- [By Keith Speights]
Not so merry
Merrimack Pharmaceuticals (NASDAQ: MACK ) shareholders have had reason to party since early May, with the stock surging more than 60%. The merriment came to a stop this week, though, as shares tanked by 27%. - [By Roberto Pedone]
One under-$10 biopharmaceuticals player that's just starting to trigger a breakout trade is Merrimack Pharmaceuticals (MACK), which focuses on discovering, developing and preparing to commercialize medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. This stock has been hit hard by the bears so far in 2013, with shares off by 38%.
If you take a look at the chart for Merrimack Pharmaceuticals, you'll notice that this stock has been downtrending badly for the last two months, with shares plunging from its high of 7.09 to its recent low of $3.26 a share. During that move, shares of MACK have been consistently making lower highs and lower lows, which is bearish technical price action. That said, shares of MACK have just formed a double bottom chart pattern at $3.26 to $3.32 a share and it's now starting to break out above some near-term overhead resistance at $3.64 a share. This move could be signaling a trend change for MACK as the stock starts to move higher off oversold conditions.
Traders should now look for long-biased trades in MACK if it manages to break out above some near-term overhead resistance at $3.64 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action of 1.87 million shares. If that breakout triggers soon, then MACK will set up to re-test or possibly take out its next major overhead resistance level at its 50-day moving average of $4.75 a share. Any high-volume move above that level and above more resistance at $5.06 will then give MACK a chance to tag its 200-day moving average at $5.71 a share.
Traders can look to buy MACK off weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $3.32 or at $3.26 a share. One can also buy MACK off strength once it clears $3.64 a share with volume and then simply use a stop tha
10 Best Clean Energy Stocks To Watch For 2014: Sigma Designs Inc.(SIGM)
Sigma Designs, Inc. provides integrated system-on-chip solutions (SoC) for the Internet protocol television (IPTV), media processor, connected home and media player, prosumer and industrial audio/video, high definition television, and PC-based add-in markets. The company offers semiconductors with a suite of real-time software that enables synchronous processing of video, audio, and graphics streams for various applications. Its media processor product line represents a family of SoC solutions that are a component of multiple consumer applications, which process digital video and audio content comprising IPTV, connected media players, and portable media players. The company?s home networking product line consists of wired networking solutions based on HomePNA, HomePlug AV, and G.hn standards, as well as wireless connectivity solutions based on Ultra-wideband technology. Its standards are used for transferring Internet protocol content across coaxial cables, phone lines, a nd power lines to enable service providers to deliver IPTV solutions and other media-rich applications. The company?s video image processor product line comprises of semiconductors that provide video output for professional and prosumer applications. Its home control and energy management automation product line includes wireless transceiver devices along with a mesh networking protocol. The company offers its home connectivity products under the CopperGate; wireless connectivity solutions under the CoAir; video image processors under the VXP; and wireless transceiver devices under the Z-Wave brands. It also provides software elements, such as multimedia library, security management software, and porting adaptations. In addition, the company offers PC-based solutions. It sells its products through direct sales force, manufacturer representatives, and independent distributors primarily in Asia, Europe, and North America. The company was founded in 1982 and is headquartered i n Milpitas, California.
Advisors' Opinion:- [By John Udovich]
We have recently added small cap video chip stock Pixelworks, Inc (NASDAQ: PXLW) to our SmallCap Network Elite Opportunity (SCN EO)�as it stands to benefit from the growth in connecting HD quality video across all mobile device platforms, as well as Smart TVs; but Silicon Image, Inc (NASDAQ: SIMG) and Sigma Designs, Inc (NASDAQ: SIGM) are also providing chips for the video or entertainment markets. Moreover, all three of these small cap stocks have recently reported earnings that might leave you feeling even more bullish.
- [By Roberto Pedone]
One technology player that insiders are loading up on here is Sigma Designs (SIGM), which provides integrated chipset solutions that serve as the foundation for consumer products including televisions, set-top boxes and video networking products. Insiders are buying this stock into decent weakness, since shares are down by 13.9% in the last three months.
Sigma Designs has a market cap of $165 million and an enterprise value of $98 million. This stock trades at a premium valuation, with a forward price-to-earnings of 29.88. Its estimated growth rate for this year is 114.2%, and for next year it's pegged at -5.9%. This is a cash-rich company, since the total cash position on its balance sheet is $61.74 million and its total debt is zero.
The CEO just bought 454,546 shares, or $2.5 million worth of stock, at $5.50 per share.
From a technical perspective, SIGM is currently trending below both its 50-day and 200-day moving averages, which is a bearish sign. This stock recently gapped down from $5.50 to below $4.40 a share with heavy downside volume. Following that move, shares of SIGM went on to hit a new low of $4.04 a share. That said, this stock has started to rebound off that $4.04 low and it's now moving within range of triggering a near-term breakout trade.
If you're bullish on SIGM, then I would look for long-biased trades as long as this stock is trending above some near-term support at $4.48 or above its recent low of $4.04, and then once breaks out above some near-term overhead resistance at $4.85 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action of 299,402 shares. If that breakout hits soon, then SIGM will set up to re-fill some of its previous gap down zone that started at $5.500 a share. This stock could even tag $5.75 to $6.20 a share if that gap gets filled with strong upside volume flows.
- [By Rebecca McClay]
In earnings news today, a few companies are reporting after the closing bell, including H & R Block Inc. (NYSE: HRB), which is up about 1%. Pike Electric Corp. (NYES: PIKE), Guidewire Software Inc. (NYSE: GWRE), and Sigma Designs Inc. (Nasdaq: SIGM) are also reporting quarterly earnings late this afternoon.
- [By GuruFocus]
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below:
Sigma Designs, Inc. (SIGM): President & CEO Thinh Q Tran Bought 454,546 SharesPresident & CEO of Sigma Designs, Inc. (SIGM) Thinh Q Tran bought 454,546 shares on 12/20/2013 at an average price of $4.65. Sigma Designs, Inc., a California corporation was incorporated in January 1982. Sigma Designs, Inc. has a market cap of $160.902 million; its shares were traded at around $4.65 with and P/S ratio of 0.77.
10 Best Clean Energy Stocks To Watch For 2014: Bona Film Group Limited(BONA)
Bona Film Group Limited distributes films in the People?s Republic of China. It distributes films to movie theaters, as well as to non-theatrical distribution channels, including DVD and Blu-ray and other home video products; Internet and digital distribution; in-flight entertainment; and cable, satellite, and broadcast televisions. The company also invests in the production of Chinese and Hong Kong films in order to obtain the distribution rights for movie theaters and non-theatrical channels. In addition, Bona Film Group operates six movie theaters in five cities of the People?s Republic of China; operates a talent agency business that represents artists; and involves in film advertising and television production businesses. The company was founded in 2003 and is headquartered in Beijing, the People?s Republic of China.
Advisors' Opinion:- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Bona Film Group (Nasdaq: BONA ) , whose recent revenue and earnings are plotted below. - [By Bryan Murphy]
With just a quick glance at the chart, Bona Film Group Ltd (NASDAQ:BONA) doesn't look like anything other than an erratic mess. When you take a step back and take a look at the longer-term chart of BONA, however, you can see the last several weeks have ushered in a major bullish change of direction for the stock... meaning now's a great time to start wading into a position.
- [By Bryan Murphy]
It's certainly no The Walt Disney Company (NYSE:DIS). It's not even a Lions Gate Entertainment Corp. (NYSE:LGF). Yet, Bona Film Group Ltd (NASDAQ:BONA) is a solid company in its own right, and BONA shares are looking more compelling right now than DIS or LGF are here, even though all three companies are in the same industry.
10 Best Clean Energy Stocks To Watch For 2014: First Trust Global Wind Energy (FAN)
First Trust ISE Global Wind Energy Index Fund is an exchange-traded fund. The investment objective of the Fund is to seek investment results that correspond generally to the price and yield, of an equity index called the ISE Global Wind Energy Index. The Fund will normally invest at least 90% of its net assets (plus the amount of any borrowings for investment purposes) in common stocks that comprise the Index or in depositary receipts that may include American depositary receipts (ADRs), global depositary receipts (GDRs), European depositary receipts (EDRs) or other depositary receipts (collectively, Depositary Receipts) representing securities in the Index. The Fund invests in sectors, which include Consumer Discretionary, Energy, Industrials, Materials and Utilities. First Trust Advisors L.P. (First Trust) is the Investment Advisor of the Fund. Advisors' Opinion:- [By John Udovich]
Small cap wind stock Broadwind Energy Inc (NASDAQ: BWEN) is up 203.7% since the start of the year, but investors might want to contain their excitement when they look closer at the�stock and�consider its�long term performance along with the performance of other wind investments like First Trust Global Wind Energy ETF (NYSEARCA: FAN) and wind energy stocks Vestas Wind Systems (OTCMKTS: VWDRY) and China Ming Yang Wind Power Group Ltd (NYSE: MY) to see whether BWEN is just blowing more hot air.
10 Best Clean Energy Stocks To Watch For 2014: Taro Pharmaceutical Industries Ltd (TARO)
Taro Pharmaceutical Industries Ltd., incorporated in 1959, is a science-based pharmaceutical company. The Company develops manufactures, and markets prescription and over-the-counter (OTC) pharmaceutical products, primarily in the United States, Canada and Israel. The Company also develops and manufactures active pharmaceutical ingredients (APIs), primarily for use in its finished dosage form products. The Company�� primary areas of focus include pediatric creams and ointments, liquids, capsules and tablets, mainly in the dermatological and topical, cardiovascular, neuropsychiatric and anti-inflammatory therapeutic categories. The Company operates through three companies: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries (including indirect), Taro Pharmaceuticals Inc. (Taro Canada) and Taro U.S.A. The Company markets more than 180 pharmaceutical products in over 25 countries.
Taro Israel manufactures more than 160 finished dosage form pharmaceutical products for sale in Israel and for export. It produces APIs used in the manufacture of finished dosage form pharmaceutical products. It markets and distributes generic products in the local Israeli market. Taro Israel�� primary product lines include dermatology, prescription and OTC semi-solid products (creams, ointments and gels) and liquids; cardiology and neurology, prescription oral dosage products; oral analgesics, both prescription and OTC, and OTC oral and nasal sprays and ophthalmic products.
Taro Canada manufactures more than 70 finished dosage form pharmaceutical products for sale in Canada and for export. It markets and distributes generic products in the local Canadian market. Its product line includes dermatology: prescription and OTC semi-solid products (creams, ointments and gels) and liquids, cardiology, oncology, gastrointestinal and neurology: prescription oral and injects able dosage products, and allergy (antihistamine): OTC oral dosage products.
Taro U.S.A markets! and distributes generic products in the United States market. Its primary product lines include dermatology: prescription and OTC semi-solid products (creams, ointments and gels) and liquids, cardiology and neurology: prescription oral dosage products, and other prescription and OTC products.
The Company competes with Bristol-Myers Squibb, GlaxoSmithKline, Merck, Novartis, Pfizer/Wyeth, Valeant, Galderma, Merck/Schering-Plough, Teva Pharmaceuticals U.S.A., Mylan Laboratories, Perrigo Company, Ranbaxy Pharmaceuticals Inc., Sandoz Pharmaceuticals, Merck Canada Inc., Pfizer Canada Inc., Janssen Inc., Schering-Plough Canada, Novartis Pharmaceuticals Canada Inc., GlaxoSmithKline Inc., Bayer Inc., Bristol-Myers Squibb Canada, Apotex Inc., Teva Canada Limited, Mylan Pharmaceuticals ULC, Sandoz Canada Incorporated, Pharmascience Inc., Teva Pharmaceutical Industries Ltd., Perrigo Israel Pharmaceuticals Ltd., Dexxon Ltd., Rafa Laboratories Ltd., Bayer AG, Eli Lilly and Company, Merck & Co., Inc. and Pfizer Inc.
Advisors' Opinion:- [By Ben Levisohn]
Teva has dropped 7.7% to $37.85 today at 3:23 p.m. but doesn’t seem to be spreading though the generic drug space. Taro Pharmaceuticals (TARO) ha gained 1.1% to $79, while Actavis (ACT) has gained 1.2% to $156.25 and Dr. Reddy’s Laboratories (RDY) has advanced 1% to $40.24. Mylan (MYL) has dropped 0.7% to $38.40.
- [By Rich Smith]
Israeli drugmaker Taro Pharmaceutical Industries (NYSE: TARO ) has a new CEO -- and a new Chairman of the Board, as well.
On Thursday, Taro announced the imminent retirement of Interim Chief Executive Officer Mr. James Kedrowsk, who will be replaced August 1 by new permanent CEO Mr. Kalyanasundaram Subramanian ("Kal Sundaram"). Additionally, the company said that Dilip Shanghvi�has been appointed Chairman of its Board of Directors.
10 Best Clean Energy Stocks To Watch For 2014: Concho Resources Inc. (CXO)
Concho Resources Inc., an independent oil and natural gas company, engages in the acquisition, development, and exploration of producing oil and natural gas properties in the United States. Its operations are focused in the Permian Basin of Southeast New Mexico and West Texas. The company also has acreage positions in the Bakken/Three Forks play in North Dakota. As of December 31, 2010, Concho Resources had estimated proved reserves of 323.5 million barrel of oil equivalent. The company is headquartered in Midland, Texas.
Advisors' Opinion:- [By ovenerio]
The company has a current ROE of 12.69% which is higher than the industry median and the ones exhibit by Encana (ECA), Crescent Point Energy (CPG), Concho Resources (CXO) and EQT (EQT). In general, analysts consider ROE ratios in the 15-20% range as representing attractive levels for investment. It is very important to understand this metric before investing and it is important to look at the trend in ROE over time.
- [By WWW.GURUFOCUS.COM]
Concho Resources, Inc. (CXO) is an independent E&P company focused on the Permian Basin in West Texas. Concho shares rose in the first quarter as the company provided greater detail about a significant increase in its oil and gas resource potential across its acreage position in the Permian and particularly in the Delaware sub-basin. The combination of the increase in the company's drilling inventory, strong initial well results and a faster than expected acceleration in its drilling inventory bode well for Concho's production growth outlook and for improvements in its net asset value. (James Stone)
10 Best Clean Energy Stocks To Watch For 2014: BlackRock Inc (BLK)
BlackRock, Inc. (BlackRock) is an independent investment management firm. The Company provides a range of investment and risk management services. The Company serves its clients as a fiduciary, and derives all of its revenues from client business. It invests in capital markets globally. Its clients include taxable, tax-exempt and official institutions (including pension funds, endowments, insurance companies, corporations, financial institutions, central banks and sovereign wealth funds) as well as retail investors and high net worth individuals. Its product range includes single- and multi-asset class portfolios investing in equities, fixed income, alternatives and/or money market instruments. It offer its products directly and through intermediaries in a range of vehicles, including open-end and closed-end mutual funds, iShares exchange-traded funds (ETFs) and other exchange-traded products ( ETPs), collective investment funds and separate accounts. The Company also offers its BlackRock Solutions (BRS) investment systems, risk management and advisory services to institutional investors. In March 2012, it acquired Claymore Investments, Inc. from Guggenheim Partners, LLC.
Equity and Fixed Income
Equity and fixed income assets under management (AUM) include a range of active and passive strategies. Merger-related outflows in equities and fixed income, respectively, due to manager concentration.
Multi-Asset Class
BlackRock�� multi-asset class team manages a range of bespoke mandates. Investment solutions include a combination of long-only portfolios and alternative investments, as well as tactical asset allocation overlays. As of December 31, 2011, institutional investors represented 63% of multi-asset class AUM, while retail and high net worth investors accounted for 37%. Flows were almost evenly split as well. During the year ended December 31, 2011, with 55% of multi-asset class AUM managed for clients based in the Americas, 38% in Europe, the Mi! ddle East and Africa (EMEA) and 7% in Asia-Pacific. As of December 31, 2011, asset allocation and balanced products represented 56% of multi-asset class AUM. As of December 31, 2011, fiduciary management services accounted for 22% of multi-asset class AUM. As of December 31, 2011, target date and target risk funds is 22% of multi-asset class AUM.
Alternative Investments
As of December 31, 2011, the alternative investment client base was predominantly institutional, representing 73% of alternatives AUM with retail and high net worth investors comprising an additional 9% of AUM. As of December31, 2011, iShares consisted 18% of ending AUM. The geographic mix was well diversified, with 56% of AUM managed for clients in the Americas, 22% for clients in EMEA and 22% for clients in Asia-Pacific. The BlackRock Alternative Investors (BAI) group coordinates its alternative investment efforts, including product management, business development and client service. The products offered under the BAI umbrella are: core, which includes hedge funds, funds of funds and real estate offerings, and currency and commodities. Offerings include high yield debt and core, value-added and opportunistic equity portfolios. It also offers open-end hedge funds and similar products and closed-end funds. These products include a range of active and passive products managed through institutional separate accounts.
Cash Management and Securities Lending
Cash management products include taxable and tax-exempt money market funds and customized separate accounts. Portfolios may be denominated in the United States dollar, euro or pound sterling. As of December 31, 20110, its cash management clientele is institutional, with 84% of cash AUM managed for institutions and 16% for retail and high net worth investors. The investor base was also domestic, with 70% managed for investors in the Americas and 30% for clients in other regions, almost all EMEA-based.
Active Strategies
! The Company offers two types of active strategies: those that rely primarily on fundamental research and those that utilize primarily quantitative models to drive security selection and portfolio construction. As of December 31, 2011, active long-term AUM consisted of 23% equities, 52% fixed income, 18% multi-asset and 7% alternatives.
Active Equity
A range of products are offered, including global and regional portfolios; value, growth and core products; large, mid and small cap strategies, and selected sector funds. BlackRock manages active equity portfolios for a range of institutional and retail and high net worth investors globally. Approximately 48% of its active equity AUM was managed for investors based in the Americas, 38% in EMEA and 14% in Asia-Pacific.
Active Fixed Income
Fixed income mandates are tailored to client-specified liabilities, accounting, regulatory or rating agency requirements, or other investment policies. As of December 31, 2011, of BlackRock�� total active fixed income AUM, 81% was managed on behalf of institutional investors and 19% for retail and high net worth investors. The client base reflects 70% of active fixed income AUM managed for investors in the Americas, 21% for EMEA domiciled clients, and 9% for investors in the Asia-Pacific region.
Multi-Asset and Alternatives
During 2011, 97% of AUM in multi-asset class mandates, and 76% of AUM in alternative investments are managed in active strategies. As of December 31, 2011, equity products consisted 64% of institutional index AUM. Fixed income products represented 35% of institutional index AUM. Less than 1% of institutional index AUM is in alternatives or multi-asset class products.
iShares / ETPs
During 2011, the Company introduced 45 new ETPs, maintaining dual commitment innovation and responsible product structuring. Its product range offers investors the building blocks required to assemble diversified portfolio! s. As of ! December 31, 2011, its iShares product mix included 71%, in equity offerings, and 26%, in fixed income ETPs and 3%, in multi-asset class and alternative investments. In addition, the Company is an ETF manager in Mexico and has products in Chile, Peru, Brazil, Australia, Hong Kong and Japan. In addition, the Company is the ETP manager in Latin America.
BlackRock Solutions
BlackRock offers investment systems, risk management, outsourcing and advisory services under the BlackRock Solutions brand name. Its Aladdin operating platform serves as the investment system for BlackRock and institutional investors globally. BRS also offers comprehensive risk reporting through the Green Package and risk management advisory services, interactive fixed income analytics through its Web-based calculator, AnSer, middle and back office outsourcing services and investment accounting. Clients have also retained BRS��Financial Markets Advisory (FMA) group for a range of engagements, such as valuation and risk assessment of illiquid assets, portfolio restructuring, workouts and dispositions of distressed assets and financial and balance sheet strategies.
Transition Management Services
BlackRock also offers transition management services, involving the temporary oversight of a client�� assets as they transition from one manager to another or from one strategy to another. It provides service that includes project management and implementation based on achieving execution consistent with the client�� risk management tolerances. The average transition assignment is executed within three weeks. These portfolios are not included in AUM unless BlackRock has been retained to manage the assets after the transition phase.
Risk & Quantitative Analysis
Across all asset classes, the Risk & Quantitative Analysis (RQA) group at BlackRock provides risk management advice and independent risk oversight of the investment management processes, identifies and hel! ps manage! counterparty and operational risks, coordinates standards for firm wide investment performance measurement and determines risk management-related analytical and information requirements.
Advisors' Opinion:- [By Tom Taulli]
Retail Investors: KKR has dealt primarily with institutions and governments. But over the past couple years, it has been building a platform — such as with exchange-traded funds — for individual investors. However, there are some issues. �While the market is substantial, there remains tremendous competition from players like Charles Schwab (SCHW) and BlackRock (BLK). For the most part, KKR has seen little traction. Even worse, it could be a distraction from its more profitable core business.
- [By Lauren Pollock]
BlackRock Inc.(BLK) rode the fourth-quarter U.S. stock rally to new highs, growing assets under management to $4.32 trillion and boosting its profit by 22% from the year-ago quarter. The results, which topped Wall Street expectations, allowed the world’s largest asset manager to boost its quarterly dividend to $1.93 a share from $1.68. shares rallied in premarket trading, up 3.9% to $324.88.
- [By Monica Gerson]
BlackRock (NYSE: BLK) is projected to report its Q3 earnings at $3.88 per share on revenue of $2.48 billion.
U.S. Bancorp (NYSE: USB) is expected to report its Q3 earnings at $0.76 per share on revenue of $4.96 billion.
- [By John Grgurich]
Also on the minds of B of A investors in particular is the trial currently under way between the superbank, AIG (NYSE: AIG ) , Bank of New York Mellon, BlackRock (NYSE: BLK ) , PIMCO, and other big investors. Or should I say was under way. The case has actually been suspended mid-trial because of scheduling conflicts on the part of presiding judge Barbara Kapnick.
No comments:
Post a Comment